Perspectives on Precision Oncology Issue 5

In this review:
The rise of precision oncology has led to a massive increase in demand for clinical genetics services and input to molecular tumour boards. In part, this is a direct reflection of increasing understanding of the implications of specific mutations for the response to chemotherapy agents, and prognostic implications (such as BRCA mutations in those with breast and ovarian cancer). This is also driven by the now routine use of large somatic panels in patients with cancer, where testing may uncover a potentially inherited mutation in a cancer predisposition gene, either one related to the tumour or picked up incidentally.

Please login below to download this issue (PDF)